Hind Sbihi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hind Sbihi has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Michael Brauer
The University of British Columbia
8 shared publications - Naveed Zafar Janjua
British Columbia Centre for Disease Control (BCCDC), Vancouver, BC V5Z 4R4, Canada
7 shared publications Sharmistha Mishra
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; MAP Centre for Urban Health Solutions, Unity Health Toronto, Ontario, Canada; Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
7 shared publications- Sharmistha Mishra
University of Toronto
7 shared publications - Beate Sander
Health Systems and Policy Research Collaborative Centre, University Health Network, Toronto, ON M5G 2C4, Canada
6 shared publications - Jeffrey C. Kwong
Dalla Lana School of Public Health, University of Toronto , Toronto, Ontario
6 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Elsevier in SSRN Electronic Journal
Healthcare Utilization among People Living with Long COVID More Than Two Years after Acute Infection
Background: Understanding the long-term impact of Long COVID on healthcare utilization is critical for healthcare planning, yet data beyond the first post-acute year remain limited.Methods: This retrospective cohort study assessed healthcare utilization among adult COVID-19 survivors in British Columbia, Canada, comparing those with and without Long COVID over three years following infection. Inverse probability of treatment weighting was used to balance cohorts on key variables. Healthcare utilization, defined as daily rates of outpatient visits, emergency department visits, and hospitalizations, was measured across four periods: 26-week pre-infection baseline, 0–26 weeks, 13–18 months, and 25–30 months post-infection. Difference-in-differences analyses using weighted multivariable Poisson regression estimated adjusted ratios of rate ratios (aRRR).Findings: The weighted cohort included 666,092 participants, of whom 327,323 had Long COVID (53.6% female; mean age 47.85 [SD 18.68]). In the first 6 months post-infection, healthcare utilization more than doubled in the Long COVID group (67.02 vs. 30.75 per 1,000) compared to a modest increase in those without Long COVID (23.81 vs. 18.95). Although utilization declined over 2.5 years (50.39 per 1,000), it remained elevated. Relative to baseline, utilization was 64% higher at 0–6 months (aRRR 1.64, 95% CI 1.54–1.73) and 55% higher at 25–30 months (aRRR 1.55, 95% CI 1.46–1.64).Interpretation: Long COVID is associated with persistently increased healthcare utilization for over two years post-infection, highlighting the need for long-term healthcare system planning.
- 25 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHealthcare Utilization among People Living with Long COVID More Than Two Years after Acute Infection
Background: Understanding the long-term impact of Long COVID on healthcare utilization is critical for healthcare planning, yet data beyond the first post-acute year remain limited.Methods: This retrospective cohort study assessed healthcare utilization among adult COVID-19 survivors in British Columbia, Canada, comparing those with and without Long COVID over three years following infection. Inverse probability of treatment weighting was used to balance cohorts on key variables. Healthcare utilization, defined as daily rates of outpatient visits, emergency department visits, and hospitalizations, was measured across four periods: 26-week pre-infection baseline, 0–26 weeks, 13–18 months, and 25–30 months post-infection. Difference-in-differences analyses using weighted multivariable Poisson regression estimated adjusted ratios of rate ratios (aRRR).Findings: The weighted cohort included 666,092 participants, of whom 327,323 had Long COVID (53.6% female; mean age 47.85 [SD 18.68]). In the first 6 months post-infection, healthcare utilization more than doubled in the Long COVID group (67.02 vs. 30.75 per 1,000) compared to a modest increase in those without Long COVID (23.81 vs. 18.95). Although utilization declined over 2.5 years (50.39 per 1,000), it remained elevated. Relative to baseline, utilization was 64% higher at 0–6 months (aRRR 1.64, 95% CI 1.54–1.73) and 55% higher at 25–30 months (aRRR 1.55, 95% CI 1.46–1.64).Interpretation: Long COVID is associated with persistently increased healthcare utilization for over two years post-infection, highlighting the need for long-term healthcare system planning.
- Open Access
- 7 March 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (7) , 2020-2028
Examining the interaction between area-level immunity coverage and individual-level immunity to help quantify indirect herd benefits: a population-based retrospective cohort study of COVID-19 diagnoses and deaths
Empirical evidence on the indirect herd benefits of COVID-19 vaccination and/or prior infection is limited. We examined how area-level immunity interacts with individual-level immunity to affect COVID-19 diagnoses and deaths. Ontario residents aged ≥18 years were followed from August 1, 2021, to January 30, 2022. Individual-level immunity was defined as receipt of a primary series of COVID-19 vaccines or a positive SARS-CoV-2 test in the past 165 days. Area-level immunity was based on the proportion of immune individuals in an individual's residing area. Logistic regression and cause-specific hazard models were used to examine the relationship between immunity and COVID-19 diagnosis, and between immunity and COVID-19 death, with an interaction term between individual-level and area-level immunity. Of 11 122 816 adults, 7 518 015 (67.6%) were classified as having individual-level immunity at baseline. After accounting for potential confounders, area-level immunity (highest vs. lowest quintiles) was associated with lower odds of COVID-19 diagnosis. Higher area-level immunity (highest vs. lowest quintiles) was also associated with lower hazard of COVID-19 death among non-immune individuals (hazard ratio, 0.77 [0.60, 1.00]). Findings provide evidence supporting the herd benefits of vaccination or prior infection on COVID-19 diagnosis and deaths, and provide insights for interpreting vaccine effectiveness estimates in the context of herd immunity.
- 7 March 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (7) , 2020-2028
Open AccessExamining the interaction between area-level immunity coverage and individual-level immunity to help quantify indirect herd benefits: a population-based retrospective cohort study of COVID-19 diagnoses and deaths
Empirical evidence on the indirect herd benefits of COVID-19 vaccination and/or prior infection is limited. We examined how area-level immunity interacts with individual-level immunity to affect COVID-19 diagnoses and deaths. Ontario residents aged ≥18 years were followed from August 1, 2021, to January 30, 2022. Individual-level immunity was defined as receipt of a primary series of COVID-19 vaccines or a positive SARS-CoV-2 test in the past 165 days. Area-level immunity was based on the proportion of immune individuals in an individual's residing area. Logistic regression and cause-specific hazard models were used to examine the relationship between immunity and COVID-19 diagnosis, and between immunity and COVID-19 death, with an interaction term between individual-level and area-level immunity. Of 11 122 816 adults, 7 518 015 (67.6%) were classified as having individual-level immunity at baseline. After accounting for potential confounders, area-level immunity (highest vs. lowest quintiles) was associated with lower odds of COVID-19 diagnosis. Higher area-level immunity (highest vs. lowest quintiles) was also associated with lower hazard of COVID-19 death among non-immune individuals (hazard ratio, 0.77 [0.60, 1.00]). Findings provide evidence supporting the herd benefits of vaccination or prior infection on COVID-19 diagnosis and deaths, and provide insights for interpreting vaccine effectiveness estimates in the context of herd immunity.
- Open Access
- 4 March 2026
- Published by Elsevier in Environmental Research
- Vol. 298, 124124
Neighborhood playability and early childhood development: a population-based birth cohort study
- 4 March 2026
- Published by Elsevier in Environmental Research
- Vol. 298, 124124
Open AccessNeighborhood playability and early childhood development: a population-based birth cohort study
- Open Access
RSV and all-cause lower respiratory infection burden among infants in remote British Columbia: Retrospective population-based birth cohort study
Background: In 2024, the National Advisory Committee on Immunization recommended universal RSV immunization across Canada, prioritizing infants in remote communities. However, in the absence of population-based data, programs may not effectively narrow health gaps in remote communities. Methods: Retrospective cohort study of all births in British Columbia (BC) from April 2013 to March 2024, followed for 1 year, using health administrative data. Main outcomes were hospitalizations for all-cause and RSV-lower respiratory tract infection (LRTI). Secondary outcomes were tertiary Pediatric Intensive Care Unit (PICU) admissions, length of stay, and air transport. Main exposures were community remoteness and social determinants of health. Incidence rates and incidence rate ratios (IRR) adjusted for sex, prematurity, and chronic conditions were estimated using Poisson generalized estimating equations. Results: Among 472,623 infants, those living in remote communities (N=3636) had higher hospitalization risk for all-cause (IRR: 2.91, 95%CI 2.02-3.65) and RSV-LRTIs (IRR: 1.60, 95%CI 1.17-2.19) compared to metropolitan areas. Length of stay and PICU admission rates were similar by region. Almost half (48.8%) of children from remote areas hospitalized for all-cause LRTIs required air evacuation. Infants from remote communities remained at higher risk for all-cause (aIRR 2.84, 95% CI 2.22-3.63) and RSV-LRTI (aIRR 1.56, 95% CI 1.15-2.12) hospitalizations after adjusting for covariates. Interpretation: Infants in remote communities experienced a disproportionately high RSV-LRTI burden, supporting prioritized RSV interventions in these regions. The residual risk after accounting for known factors highlights the need to investigate additional drivers of vulnerability in remote areas.
Open AccessRSV and all-cause lower respiratory infection burden among infants in remote British Columbia: Retrospective population-based birth cohort study
Background: In 2024, the National Advisory Committee on Immunization recommended universal RSV immunization across Canada, prioritizing infants in remote communities. However, in the absence of population-based data, programs may not effectively narrow health gaps in remote communities. Methods: Retrospective cohort study of all births in British Columbia (BC) from April 2013 to March 2024, followed for 1 year, using health administrative data. Main outcomes were hospitalizations for all-cause and RSV-lower respiratory tract infection (LRTI). Secondary outcomes were tertiary Pediatric Intensive Care Unit (PICU) admissions, length of stay, and air transport. Main exposures were community remoteness and social determinants of health. Incidence rates and incidence rate ratios (IRR) adjusted for sex, prematurity, and chronic conditions were estimated using Poisson generalized estimating equations. Results: Among 472,623 infants, those living in remote communities (N=3636) had higher hospitalization risk for all-cause (IRR: 2.91, 95%CI 2.02-3.65) and RSV-LRTIs (IRR: 1.60, 95%CI 1.17-2.19) compared to metropolitan areas. Length of stay and PICU admission rates were similar by region. Almost half (48.8%) of children from remote areas hospitalized for all-cause LRTIs required air evacuation. Infants from remote communities remained at higher risk for all-cause (aIRR 2.84, 95% CI 2.22-3.63) and RSV-LRTI (aIRR 1.56, 95% CI 1.15-2.12) hospitalizations after adjusting for covariates. Interpretation: Infants in remote communities experienced a disproportionately high RSV-LRTI burden, supporting prioritized RSV interventions in these regions. The residual risk after accounting for known factors highlights the need to investigate additional drivers of vulnerability in remote areas.
- Open Access
- 20 November 2025
- Published by Elsevier in Environment International
- Vol. 206, 109922
Spatiotemporal estimation of actively shedding mpox virus, clade IIb, cases using wastewater signals in British Columbia, Canada
- 20 November 2025
- Published by Elsevier in Environment International
- Vol. 206, 109922
Open AccessSpatiotemporal estimation of actively shedding mpox virus, clade IIb, cases using wastewater signals in British Columbia, Canada
- Open Access
Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada
- Open Access
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002918
Associations between social determinants of health and COVID-19 outcomes by variants of concern: a Bayesian spatiotemporal analysis
Background: Socially and economically disadvantaged populations were disproportionately affected by COVID-19, but it remains unclear whether and how variants of concern moderated the associations between social determinants of health and COVID-19 outcomes. Methods: We aggregated cases by week and health region (n=231) from 1 January 2021 to 27 February 2022, covering four major variants of concern waves–Alpha, Gamma, Delta and Omicron–in British Columbia, the third most populated province in Canada. We constructed a region-specific, continuous socioeconomic index (SI) in which a one-unit increase represents a 10% increase in socioeconomic status across the health region. We fitted Bayesian spatiotemporal models on four COVID-19 outcomes separately: cases, hospitalisations, intensive care unit admissions and deaths, adjusting for interaction between SI and variants of concern, percentage male and vaccine coverage. We estimated the marginal rate ratio (RR) between SI and the outcomes by variants of concern. Results: Overall, Alpha, Gamma and Delta heightened the associations between SI and all outcomes. The marginal RR between SI and cases was 0.96 (95% credible interval (CrI): 0.93, 1.00) in the absence of variants of concern, 0.93 (95% CrI: 0.88, 0.97) in the presence of Alpha, 0.93 (95% CrI: 0.88, 0.98) for Gamma and 0.90 (95% CrI: 0.87, 0.93) for Delta. Omicron reversed the direction of SI’s association with cases (RR: 1.03, 95% CrI: 0.99, 1.07) and dampened the associations with other outcomes. Conclusions: Variants of concern generally widened the socioeconomic disparities in COVID-19 outcomes. Tailoring and optimising pandemic preparedness and response measures to the specific needs of disadvantaged populations is vital for reducing the additional disease burden experienced by some communities in British Columbia and across Canada.
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002918
Open AccessAssociations between social determinants of health and COVID-19 outcomes by variants of concern: a Bayesian spatiotemporal analysis
Background: Socially and economically disadvantaged populations were disproportionately affected by COVID-19, but it remains unclear whether and how variants of concern moderated the associations between social determinants of health and COVID-19 outcomes. Methods: We aggregated cases by week and health region (n=231) from 1 January 2021 to 27 February 2022, covering four major variants of concern waves–Alpha, Gamma, Delta and Omicron–in British Columbia, the third most populated province in Canada. We constructed a region-specific, continuous socioeconomic index (SI) in which a one-unit increase represents a 10% increase in socioeconomic status across the health region. We fitted Bayesian spatiotemporal models on four COVID-19 outcomes separately: cases, hospitalisations, intensive care unit admissions and deaths, adjusting for interaction between SI and variants of concern, percentage male and vaccine coverage. We estimated the marginal rate ratio (RR) between SI and the outcomes by variants of concern. Results: Overall, Alpha, Gamma and Delta heightened the associations between SI and all outcomes. The marginal RR between SI and cases was 0.96 (95% credible interval (CrI): 0.93, 1.00) in the absence of variants of concern, 0.93 (95% CrI: 0.88, 0.97) in the presence of Alpha, 0.93 (95% CrI: 0.88, 0.98) for Gamma and 0.90 (95% CrI: 0.87, 0.93) for Delta. Omicron reversed the direction of SI’s association with cases (RR: 1.03, 95% CrI: 0.99, 1.07) and dampened the associations with other outcomes. Conclusions: Variants of concern generally widened the socioeconomic disparities in COVID-19 outcomes. Tailoring and optimising pandemic preparedness and response measures to the specific needs of disadvantaged populations is vital for reducing the additional disease burden experienced by some communities in British Columbia and across Canada.
- Open Access
- 24 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study
Observational studies are essential for measuring vaccine effectiveness. Recent research has raised concerns about how a relationship between testing and vaccination may affect estimates of vaccine effectiveness against symptomatic infection (symptomatic VE). Using an agent-based network model and SARS-CoV-2 as an example, we investigated how differences in the likelihood of testing by vaccination could influence estimates of symptomatic VE across two common study designs: retrospective cohort and test-negative designs. First, we measured the influence of unequal testing on symptomatic VE estimates across study designs and sampling periods. Next, we investigated whether the magnitude of bias in VE estimates from unequal testing was shaped by immune escape (vaccine efficacy against susceptibility and against infectiousness) and underlying epidemic potential (probability of transmission). We found that unequal testing led to larger bias in the cohort design than the test-negative design and that bias was largest with lower efficacy against susceptibility. We also found the magnitude of bias was moderated by the study’s selected sampling period, efficacy against infectiousness, and probability of transmission, with these moderating effects more pronounced in the test-negative design. Our study illustrates that VE estimates across study designs require careful interpretation, especially in the presence of epidemic and immunological heterogeneity.
- 24 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessImpact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study
Observational studies are essential for measuring vaccine effectiveness. Recent research has raised concerns about how a relationship between testing and vaccination may affect estimates of vaccine effectiveness against symptomatic infection (symptomatic VE). Using an agent-based network model and SARS-CoV-2 as an example, we investigated how differences in the likelihood of testing by vaccination could influence estimates of symptomatic VE across two common study designs: retrospective cohort and test-negative designs. First, we measured the influence of unequal testing on symptomatic VE estimates across study designs and sampling periods. Next, we investigated whether the magnitude of bias in VE estimates from unequal testing was shaped by immune escape (vaccine efficacy against susceptibility and against infectiousness) and underlying epidemic potential (probability of transmission). We found that unequal testing led to larger bias in the cohort design than the test-negative design and that bias was largest with lower efficacy against susceptibility. We also found the magnitude of bias was moderated by the study’s selected sampling period, efficacy against infectiousness, and probability of transmission, with these moderating effects more pronounced in the test-negative design. Our study illustrates that VE estimates across study designs require careful interpretation, especially in the presence of epidemic and immunological heterogeneity.
- Open Access
- 9 May 2025
- Published by Elsevier in Environment International
- Vol. 200, 109524
Residential exposure to noise, green space, and children’s language acquisition
- 9 May 2025
- Published by Elsevier in Environment International
- Vol. 200, 109524
Open AccessResidential exposure to noise, green space, and children’s language acquisition